Literature DB >> 10571932

Theoretical limits of spatial resolution in elliptical-centric contrast-enhanced 3D-MRA.

S B Fain1, S J Riederer, M A Bernstein, J Huston.   

Abstract

The point spread function (PSF) for contrast-enhanced three-dimensional (3D) MR angiography using the elliptical centric view order is derived. This view order has been shown previously to provide high venous suppression thereby enabling long acquisition times capable of high spatial resolution. The dependence of the PSF on TR, field of view (FOV), scan time, and trigger time are shown explicitly. Theoretical predictions are corroborated with experimental results in phantoms and in vivo. The PSF width decreases as the square root of the product of TR and the two phase encoding FOV's for fixed nominal voxel size. The PSF peak amplitude increases as the reciprocal of this product. Theory and experiment demonstrate that acquisition times over 40 sec provide superior resolution compared to shorter acquisitions, despite falling levels of contrast agent concentration. The analysis predicts that an isotropic spatial resolution of 1 mm before zero filling is possible in a FOV large enough to encompass the carotid and vertebral arteries bilaterally. Magn Reson Med 42:1106-1116, 1999. Copyright 1999 Wiley-Liss, Inc.

Mesh:

Substances:

Year:  1999        PMID: 10571932     DOI: 10.1002/(sici)1522-2594(199912)42:6<1106::aid-mrm15>3.0.co;2-q

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  9 in total

1.  Contrast-enhanced MR angiography: the effects of k-space truncation on luminal representation in a carotid artery phantom model.

Authors:  E R Melhem; J M Serfaty; L Jones; R Itoh; B S Kuszyk; J B Martin; P Gailloud; K P Murphy; D A Rufenacht
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

2.  Intrinsic signal amplification in the application of 2D SENSE parallel imaging to 3D contrast-enhanced elliptical centric MRA and MRV.

Authors:  Stephen J Riederer; Houchun Harry Hu; David G Kruger; Clifton R Haider; Norbert G Campeau; John Huston
Journal:  Magn Reson Med       Date:  2007-11       Impact factor: 4.668

Review 3.  Whole-Body MRA.

Authors:  Harald Kramer; Harald H Quick; Bernd Tombach; Stefan O Schoenberg; Joerg Barkhausen
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

4.  Partial fourier shells trajectory for non-cartesian MRI.

Authors:  Shengzhen Tao; Yunhong Shu; Joshua D Trzasko; John Huston; Matt A Bernstein
Journal:  Phys Med Biol       Date:  2019-02-06       Impact factor: 3.609

5.  Magnetization-prepared shells trajectory with automated gradient waveform design.

Authors:  Yunhong Shu; Shengzhen Tao; Joshua D Trzasko; John Huston; Paul T Weavers; Matt A Bernstein
Journal:  Magn Reson Med       Date:  2017-08-21       Impact factor: 4.668

6.  Sparse-CAPR: highly accelerated 4D CE-MRA with parallel imaging and nonconvex compressive sensing.

Authors:  Joshua D Trzasko; Clifton R Haider; Eric A Borisch; Norbert G Campeau; James F Glockner; Stephen J Riederer; Armando Manduca
Journal:  Magn Reson Med       Date:  2011-05-23       Impact factor: 4.668

7.  Buildup of image quality in view-shared time-resolved 3D CE-MRA.

Authors:  Casey P Johnson; Thomas W Polley; James F Glockner; Phillip M Young; Stephen J Riederer
Journal:  Magn Reson Med       Date:  2012-08-30       Impact factor: 4.668

8.  High-spatial-resolution contrast-enhanced MR angiography of the intracranial venous system with fourfold accelerated two-dimensional sensitivity encoding.

Authors:  Houchun H Hu; Norbert G Campeau; John Huston; David G Kruger; Clifton R Haider; Stephen J Riederer
Journal:  Radiology       Date:  2007-04-19       Impact factor: 11.105

9.  On the dual contrast enhancement mechanism in frequency-selective inversion-recovery magnetic resonance angiography (IRON-MRA).

Authors:  Evert-jan Vonken; Grigorios Korosoglou; Jing Yu; Michael Schär; Ralph Weissleder; Matthias Stuber
Journal:  Magn Reson Med       Date:  2009-08       Impact factor: 4.668

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.